First WRN Helicase Inhibitor Shows Promising Results in MSI Solid Tumors
A first-in-human phase 1 trial of RO7589831, a covalent WRN helicase inhibitor, demonstrates manageable safety and early antitumor activity in MSI cancers.
Summary
Werner syndrome helicase (WRN) is a DNA repair enzyme that microsatellite instability (MSI) cancers depend on for survival — making it an ideal synthetic lethal target. Researchers tested RO7589831, the first drug designed to block WRN, in 88 patients with advanced MSI solid tumors. The drug was given at various doses and schedules. Side effects were mostly mild, with nausea, diarrhea, fatigue, and anemia being most common. No treatment-related deaths occurred. Among evaluable MSI patients, 74% achieved disease control, and about 11% had confirmed tumor shrinkage. Median progression-free survival reached 6.7 months, and median overall survival was 17.6 months. Two doses were selected for further testing. These early results position WRN inhibition as a promising new approach for MSI cancers that have progressed beyond standard therapies.
Detailed Summary
Cancers driven by defective DNA mismatch repair (dMMR) or microsatellite instability (MSI) are particularly dependent on an alternative DNA repair pathway involving the Werner syndrome helicase (WRN). Blocking WRN creates a synthetic lethal effect specifically in these cancers, sparing normal cells — a mechanistic rationale that makes WRN an attractive drug target. This is especially relevant for patients who have progressed on immunotherapy, which is currently the standard of care for MSI tumors.
This first-in-human phase 1 trial enrolled 88 patients with advanced MSI or dMMR solid tumors across multiple international sites. Participants received RO7589831 (VVD-133214), a novel covalent WRN inhibitor developed by Roche and Vividion Therapeutics, at escalating doses ranging from once-daily 150 mg to three-times-daily 600 mg. The primary goals were to establish safety, tolerability, and the recommended phase 2 dose (RP2D).
The drug demonstrated a manageable safety profile. The most common side effects — nausea, diarrhea, fatigue, anemia, and vomiting — were predominantly grade 1 or 2. Severe grade 3 or higher adverse events were infrequent, and no treatment-related deaths occurred. Only 3.4% of patients discontinued due to side effects, and the maximum tolerated dose was not reached. Two doses — 150 mg and 600 mg twice daily — were selected as RP2Ds for further optimization.
For efficacy, among MSI evaluable patients, the disease control rate was 74.2%, with 7 patients achieving confirmed partial tumor responses (ORR 10.6%). Median duration of response exceeded 10 months. Median progression-free survival was 6.7 months and median overall survival was 17.6 months. Exploratory biomarker analyses using circulating tumor DNA and FDG-PET imaging supported biological activity, even though direct tumor tissue target engagement could not be confirmed.
These results support continued investigation of WRN inhibition as a synthetic lethal strategy. Limitations include the phase 1 design, small patient numbers, heterogeneous tumor types, and reliance on the abstract alone for this summary.
Key Findings
- Disease control rate of 74.2% achieved in MSI-evaluable patients with advanced solid tumors.
- Objective response rate of 10.6% with median duration of response exceeding 10 months.
- Median overall survival reached 17.6 months; median progression-free survival was 6.7 months.
- Safety profile was manageable — no grade 5 events; only 3.4% discontinued due to adverse effects.
- 150 mg and 600 mg twice-daily doses selected as recommended phase 2 doses for further testing.
Methodology
This was part 1 of an ongoing, first-in-human phase 1 dose-escalation trial (NCT06004245) enrolling 88 patients with advanced MSI or dMMR solid tumors across multiple international centers. RO7589831 was administered at escalating doses and schedules (once daily, twice daily, or three times daily) to determine safety, tolerability, and the RP2D. Secondary endpoints included antitumor activity assessed by RECIST v1.1, with exploratory ctDNA and FDG-PET biomarker analyses.
Study Limitations
This summary is based on the abstract only, as the full paper is not open access, which limits detailed assessment of patient characteristics, tumor subtypes, and exploratory analyses. The phase 1 design with a heterogeneous patient population limits efficacy conclusions, and response rates were modest. Direct tumor tissue target engagement could not be demonstrated, leaving some uncertainty about the drug's on-target mechanism in vivo.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.
Enter your email to subscribe: